Biological mechanism profiling using an annotated compound library

Chemistry and Biology

Volumn 10, Issue 9, 2003, Pages 881-892

  Root, David E ^a   Flaherty, Stephen P ^a   Kelley, Brian P ^a   Stockwell, Brent R ^a  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0141521869     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2003.08.009     Document Type: Article

References (50)

1. Mitchison T.J. Towards a pharmacological genetics. Chem. Biol. 1:1994;3-6.
2. Schreiber S.L. Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg. Med. Chem. 6:1998;1127-1152.
3. Stockwell B.R. Chemical genetics. ligand-based discovery of gene function Nat. Rev. Genet. 1:2000;116-125.
4. Stockwell B.R. Frontiers in chemical genetics. Trends Biotechnol. 18:2000;449-455.
5. Brown P.O., Botstein D. Exploring the new world of the genome with DNA microarrays. Nat. Genet. 21:1999;33-37.
6. Maeda I., Kohara Y., Yamamoto M., Sugimoto A. Large-scale analysis of gene function in Caenorhabditis elegans by high-throughput RNAi. Curr. Biol. 11:2001;171-176.
7. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
8. Weinstein J.N., Buolamwini J.K. Molecular targets in cancer drug discovery. cell-based profiling Curr. Pharm. Des. 6:2000;473-483.
9. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornace A.J. Jr., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L.et al. An information-intensive approach to the molecular pharmacology of cancer. Science. 275:1997;343-349.
10. Shi L.M., Fan Y., Lee J.K., Waltham M., Andrews D.T., Scherf U., Paull K.D., Weinstein J.N. Mining and visualizing large anticancer drug discovery databases. J. Chem. Inf. Comput. Sci. 40:2000;367-379.
11. Liu L.F., Desai S.D., Li T.K., Mao Y., Sun M., Sim S.P. Mechanism of action of camptothecin. Ann. N Y Acad. Sci. 922:2000;1-10.
12. Long B.H., Stringfellow D.A. Inhibitors of topoisomerase II. structure-activity relationships and mechanism of action of podophyllin congeners Adv. Enzyme Regul. 27:1988;223-256.
13. Miller M.L., Ojima I. Chemistry and chemical biology of taxane anticancer agents. Chem. Rec. 1:2001;195-211.
14. Zalacain M., Zaera E., Vazquez D., Jimenez A. The mode of action of the antitumor drug bouvardin, an inhibitor of protein synthesis in eukaryotic cells. FEBS Lett. 148:1982;95-97.
15. Stockwell B.R., Hardwick J.S., Tong J.K., Schreiber S.L. Chemical genetic and genomic approaches reveal a role for copper in specific gene activation. J. Am. Chem. Soc. 121:1999;10662-10663.
16. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., Mitchison T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 286:1999;971-974.
17. Peterson R.T., Link B.A., Dowling J.E., Schreiber S.L. Small molecule developmental screens reveal the logic and timing of vertebrate development. Proc. Natl. Acad. Sci. USA. 97:2000;12965-12969.
18. Darvas F., Dorman G., Papp A. Diversity measures for enhancing ADME admissibility of combinatorial libraries. J. Chem. Inf. Comput. Sci. 40:2000;314-322.
19. Kohonen, T. (2001). Self-Organizing Maps, Volume 30 (Berlin: Springer).
20. Markham P.N., Westhaus E., Klyachko K., Johnson M.E., Neyfakh A.A. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1999;2404-2408.
21. Dolma S., Lessnick S.L., Hahn W.C., Stockwell B.R. Identification of genotype-selective anti-tumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 3:2003;285-296.
22. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.
23. Hahn W.C., Dessain S.K., Brooks M.W., King J.E., Elenbaas B., Sabatini D.M., DeCaprio J.A., Weinberg R.A. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol. 22:2002;2111-2123.
24. Wang X.M., Terasaki P.I., Rankin G.W.J., Chia D., Zhong H.P., Hardy S. A new microcellular cytotoxicity test based on calcein AM release. Hum. Immunol. 37:1993;264-270.
25. Lieber M., Smith B., Szakal A., Nelson-Rees W., Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int. J. Cancer. 17:1976;62-70.
26. Giard D.J., Aaronson S.A., Todaro G.J., Arnstein P., Kersey J.H., Dosik H., Parks W.P. In vitro cultivation of human tumors. establishment of cell lines derived from a series of solid tumors J. Natl. Cancer Inst. 51:1973;1417-1423.
27. Rindflesch, T.C., Tanabe, L., Weinstein, J.N., and Hunter, L. (2000). EDGAR: extraction of drugs, genes and relations from the biomedical literature. Pac. Symp. Biocomput. 517-528.
28. Jenssen T.K., Laegreid A., Komorowski J., Hovig E. A literature network of human genes for high-throughput analysis of gene expression. Nat. Genet. 28:2001;21-28.
29. Plunkett W., Gandhi V., Huang P., Robertson L.E., Yang L.Y., Gregoire V., Estey E., Keating M.J. Fludarabine. pharmacokinetics, mechanisms of action, and rationales for combination therapies Semin. Oncol. 20:1993;2-12.
30. DeVita, V.T., Jr. (1997). In Cancer: Principles & Practice of Oncology, V.T. DeVita, Jr., S. Hellman, and S.A. Rosenberg, eds. (Philadelphia, PA: Lippincott-Raven), pp. 333-347.
31. Denny W.A., Wakelin L.P. Mode and kinetics of DNA binding of the anti-tumour agent bisantrene. Anticancer Drug Des. 2:1987;71-77.
32. Druker B.J. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med. 8:2002;S14-S18.
33. Iwahana M., Ochi Y., Ejima A. Antiproliferative activity and mechanism of action of DZ-3358, a novel pyrimidinyl pyrazole derivative. Anticancer Res. 20:2000;785-792.
34. Di Leo A., Piccart M.J. Paclitaxel activity, dose, and schedule. data from phase III trials in metastatic breast cancer Semin. Oncol. 26:1999;27-32.
35. Kaldhusdal M., Schneitz C., Hofshagen M., Skjerve E. Reduced incidence of Clostridium perfringens-associated lesions and improved performance in broiler chickens treated with normal intestinal bacteria from adult fowl. Avian Dis. 45:2001;149-156.
36. Bala S., Kombrabail M.H., Prabhananda B.S. Effect of phloretin on ionophore mediated electroneutral transmembrane translocations of H(+), K(+) and Na(+) in phospholipid vesicles. Biochim. Biophys. Acta. 1510:2001;258-269.
37. Rabe H., Picard R., Uusi-Oukari M., Hevers W., Luddens H., Korpi E.R. Coupling between agonist and chloride ionophore sites of the GABA(A) receptor. agonist/antagonist efficacy of 4-PIOL Eur. J. Pharmacol. 409:2000;233-242.
38. Yeung C.H., Cooper T.G. Effects of the ion-channel blocker quinine on human sperm volume, kinematics and mucus penetration, and the involvement of potassium channels. Mol. Hum. Reprod. 7:2001;819-828.
39. Madden K.R., Champoux J.J. Overexpression of human topoisomerase I in baby hamster kidney cells. hypersensitivity of clonal isolates to camptothecin Cancer Res. 52:1992;525-532.
40. Eng W.K., Faucette L., Johnson R.K., Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 34:1988;755-760.
41. Hsiang Y.H., Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1988;1722-1726.
42. Champoux J.J. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I. Ann. N Y Acad. Sci. 922:2000;56-64.
43. Bjornsti M.A., Benedetti P., Viglianti G.A., Wang J.C. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I. restoration of sensitivity of the cells to the antitumor drug camptothecin Cancer Res. 49:1989;6318-6323.
44. Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y., Okada K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA. 84:1987;5565-5569.
45. D'Arpa P., Beardmore C., Liu L.F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50:1990;6919-6924.
46. Hsiang Y.H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:1989;5077-5082.
47. Traganos F., Seiter K., Feldman E., Halicka H.D., Darzynkiewicz Z. Induction of apoptosis by camptothecin and topotecan. Ann. N Y Acad. Sci. 803:1996;101-110.
48. Jacobs J.P., Garrett A.J., Merton R. Characteristics of a serially propagated human diploid cell designated MRC-9. J. Biol. Stand. 7:1979;113-122.
49. Petijean M. Applications of the radius-diameter diagram to the classification of topological and geometric shapes of chemical compounds. J. Chem. Inf. Comput. Sci. 32:1992;331-337.
50. Knoben J.E., Scott G.R., Tonelli R.J. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations. Am. J. Hosp. Pharm. 47:1990;2696-2700.